Systemic chemotherapy using a multitargeted tyrosine kinase inhibitor is an established treatment for advanced-stage tumors in various organs. Comprehensive genomic analyses using nextgeneration sequencing technology revealed the intra-and intertumor heterogeneity of human hepatocellular carcinomas (HCCs), and provided evidence for the use of therapeutic agents effective against multiple targets in tumor cells. Recently, the efficacy and safety of a multitargeted tyrosine kinase inhibitor, lenvatinib, was confirmed by a randomized global phase III trial; thus, lenvatinib was approved as first-line therapy for HCC, providing a new therapeutic option for patients at an advanced stage. In this article, we introduce the application of molecular targeted therapy using lenvatinib and discuss future aspects of therapeutic options for advanced HCC.
INTRODUCTION
H EPATOCELLULAR CARCINOMA (HCC) is the sixth most frequent cancer and the second leading cause of cancer-related deaths, and is estimated to be responsible for approximately 700 000 deaths per year worldwide. 1 For patients with early-stage HCC, surgical resection and percutaneous ablation, including radiofrequency ablation (RFA) and microwave ablation, are the main therapeutic strategies. 2 The treatment options for unresectable advanced-stage HCC, however, are limited, and the prognosis is still poor because of the high potential for intraand extrahepatic multiple recurrence and metastasis. 3, 4 Treatment recommendations for such patients include transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), and systemic chemotherapy. Although TACE and HAIC are considered effective treatments for unresectable HCC, systemic chemotherapy should be selected for patients with distant metastases and for those who do not respond to TACE or HAIC.
Systemic chemotherapy using multitargeted tyrosine kinase inhibitor (TKI) is established as a standard treatment for advanced-stage tumors in various organs. In 2007, sorafenib was approved as the first TKI for HCC based on the results of two pivotal phase III studies, and is currently acknowledged as the standard therapy for advanced HCC. 5, 6 Due to various adverse effects (AEs) and the limited efficacy of sorafenib, the identification of novel TKIs beyond sorafenib has long been desired. Nevertheless, sorafenib was the only approved TKI available for a decade, other than regorafenib, which was approved for second-line therapy, because several clinical trials failed to show the efficacy of other TKIs for HCC. [7] [8] [9] [10] [11] [12] [13] Recently, the efficacy and safety of lenvatinib was confirmed, leading to its approval as a first-line therapy and providing a new therapeutic option for patients with advanced-stage HCC.
14 In this article, we review the application of molecular targeted therapy for HCC and introduce a novel therapeutic approach for advanced HCC using lenvatinib.
playing a pivotal role in diverse biologic processes, such as cell proliferation, differentiation, migration, metabolism, and apoptosis, and promoting angiogenesis and metastasis in response to external and internal stimuli. 15, 16 Tyrosine kinases are divided into two subgroups, receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). The RTKs consist of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular catalytic domain. Ligand binding to the extracellular domains results in autophosphorylation of the tyrosine residues of the intracellular catalytic domains, which leads to activation of the signal transduction cascade within the cell. 17, 18 The RTKs include VEGFR, PDGFR, fibroblast growth factor receptor (FGFR), and epidermal growth factor receptor (EGFR) kinases (Fig. 1) . In contrast to RTKs, nRTKs possess catalytic and regulatory domains, but lack extracellular and transmembrane domains. 15 The nRTKs play a role in transducing signals from membrane receptors into the nucleus. When these tyrosine kinases become constitutively activated and independent of ligands by gene mutation or overexpression, initiation and progression of cancer are accelerated. 15 Therefore, TKIs are expected to block abnormal signal transduction pathways and serve as anticancer agents. Although some TKIs Figure 1 Receptor tyrosine kinases (RTKs) and key signaling pathways in the pathogenesis of hepatocellular carcinoma. The binding of signaling molecules to RTKs causes receptor dimerization and autophosphorylation of the tyrosine residues of the intracellular catalytic domains, which leads to activation of the signal transduction cascades such as the phosphatidylinositol 3-kinase (PI3K)/ phosphatidylinositol (3,4,5)-tris-phosphate (PIP3)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) and Ras/Raf/mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) (MEK)/ERK(MAPK) pathways. EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; NF-κB, nuclear factor-κB; PDGFR, platelet-derived growth factor receptor; RET, rearranged during transfection; VEGFR, vascular endothelial growth factor receptor. [Color figure can be viewed at wileyonlinelibrary.com] target a single tyrosine kinase, such as EGFR (gefitinib and erlotinib), most recent TKIs are designed to target multiple tyrosine kinases in many types of signaling pathways. For example, sunitinib, which is approved for imatinibresistant gastrointestinal stromal tumor (GIST) and advanced renal cell carcinoma (RCC), targets VEGFRs, PDGFRs, c-Kit, and fms-like tyrosine kinase 3, exerting both direct antitumor and anti-angiogenic activity. 19 Intratumor and intertumor heterogeneity in HCC Recent advances in whole genome/exome sequencing analyses using next-generation sequencing technologies have unveiled the remarkable genomic intratumor heterogeneity of HCC. Whole-genome sequencing analyses revealed more than 9000 mutations per human HCC sample, including somatic mutations identified in approximately 40-80 protein-coding genes. [20] [21] [22] Mutations in the telomerase reverse (TERT) promotor are the most prevalent, and affect more than 50% of hepatitis virus-related HCC and non-alcoholic fatty liver disease-related HCC. [23] [24] [25] Whole genome/exome analyses indicated that TP53 and CTNNB1 are the most frequently mutated coding genes, and chromatin modulators, including ARID1A and ARID2, are also recurrently mutated in HCC. 22, 23, 26 In addition, somatic mutations are detected in a variety of genes with various oncogenic pathways, including telomere maintenance, Wnt signaling, p53/cell cycle, oxidative stress, epigenetic regulator, PI3K-AKT-mTOR, MAPK, JAK/STAT, and hepatic differentiation. 23 These findings suggest that HCC is not caused by one particular driver mutation, but involves various carcinogenic pathways, leading to extremely heterogeneous tumor features.
Hepatocellular carcinoma occurs in the background of chronic hepatitis or cirrhosis, which leads to frequent recurrence after curative therapy. In fact, patients with HCC have a high risk of tumor recurrence even after local curative treatment by either surgical resection or RFA. 27 The recurrence rate of HCC is 15-30% within 1 year, and approximately 80% in 5 years, even after curative therapy. [28] [29] [30] These recurrences include not only intrahepatic metastases, but also multicentric occurrences. Consistently, our previous whole exome sequencing analysis of synchronously developed HCCs clearly indicated that the tumors that developed in a multicentric manner shared no common mutations, suggesting that those multiple tumors possessed different biologic features. 31 Similarly, Furuta et al. reported different genetic profiles between two recurrent HCCs that developed in the same liver after curative resection. 32 Taken together, these findings indicate that human HCC has the characteristics of both intra-and intertumor heterogeneity, and therapeutic agents targeting multiple tyrosine kinases are thus expected to be effective for treatment of advanced HCCs.
Sorafenib as first-line therapy for advanced HCC
Sorafenib is an orally active TKI approved for the treatment of unresectable HCC in more than 70 countries worldwide. Sorafenib inhibits the serine/threonine kinases that are components of the Raf/MEK/ERK pathway (Raf-1, wild-type B-Raf, and mutant V600E B-Raf), and the activity of RTKs, VEGFR1, VEGFR2, VEGFR3, and PDGFR-β (Table 1) . 5, 33, 34 Based on the hypervascular nature and upregulation of VEGF expression in HCC, sorafenib is expected to prevent tumor initiation and suppress tumor progression. Sorafenib significantly improved overall survival (OS) in patients with advanced HCC (Barcelona Clinic Liver Cancer [BCLC] stage C) in the SHARP trial in 2007 and in the Asia-Pacific study in 2008. 5, 6 In the phase III SHARP trial, 602 patients with advanced HCC (299 receiving sorafenib [400 mg twice a day] and 303 receiving placebo) were enrolled. Improvement in OS (10.7 vs. 7.0 months for sorafenib and placebo, hazard ratio [HR] = 0.69; 95% confidence interval [CI], 0.55-0.87; P < 0.001), time to progression (TTP, 5.5 vs. 2.8 months for sorafenib and placebo, P < 0.001), and disease control rate (43% vs. 32%, P = 0.002) were confirmed in the sorafenib group. 5 A similar result was confirmed by the Asia-Pacific study (OS, 6.5 vs. 4.2 months for sorafenib and placebo, HR = 0.68 [95% CI, 0.50-0.93]; P = 0.014). The marked difference in median survival time in the sorafenib arm between the SHARP trial and the Asia-Pacific study might result from the difference in patients' baseline characteristics. For example, Eastern Cooperative Oncology Group performance status (ECOG PS) 0/1/2 was 54%/38%/8% in the SHARP trial and 25.3%/69.3%/ 5.3% in the Asia-Pacific study. The rate of patients with extrahepatic spread was 53% in the SHARP trial and 68.7% in the Asia-Pacific study. In addition, baseline α-fetoprotein (AFP) levels were higher in the Asia-Pacific study than those in the SHARP trial. Common AEs observed in the sorafenib group were diarrhea, hand/foot skin reaction (HFSR), fatigue, and weight loss. According to the SHARP and Asia-Pacific studies, sorafenib has an acceptable safety profile and the incidence of HSFR is in the range of 21-45%. Hand/foot skin reaction-related dose reduction and discontinuation occurred in only 5-11.4% and 1.3% of patients, respectively. 5, 6 In Japanese and Korean patients, the incidence of HFSR increases to 48-82%. [35] [36] [37] [38] Therefore, careful monitoring and appropriate management of AEs are required during treatment with sorafenib.
Sorafenib was the first TKI to show a statistically significant improvement in OS. The benefit of sorafenib, however, was not sustained in many cases (median TTP was 2.8-5.5 months in a phase III trial), although patients with good liver function could well benefit from further therapy. 5, 6 Therefore, an effective and tolerable second-line agent for patients with advanced-stage HCC with disease progression during treatment with sorafenib is longawaited. In 2016, a survival benefit of regorafenib over placebo was reported for HCC patients showing disease progression on treatment with sorafenib. 13 
Regorafenib as second-line therapy after sorafenib
Regorafenib is an orally active TKI targeting VEGFR1-3, rearranged during transfection (RET), Kit, PDGFR, and Raf kinases (Table 1) . 39 In the phase III RESORCE trial, 573 patients with HCC who tolerated sorafenib (≥400 mg/day for ≥20 days within the last 28 days before radiological progression), progressed on sorafenib, and had Child-Pugh A liver function were enrolled across 152 sites in 21 countries. 13 The inclusion criteria were designed to prevent the risk of dropouts due to AEs associated with regorafenib, as the targeting molecules and AEs of regorafenib are similar to those of sorafenib, and to minimize the effect of post-trial treatment after disease progression. 40 A total of 379 patients were assigned to the regorafenib treatment arm (160 mg once daily during weeks 1-3 of each 4-week cycle) and 194 were assigned to the placebo arm. Randomization was stratified by geographic region, macrovascular invasion, extrahepatic spread, serum AFP concentration (<400 ng/mL vs. ≥400 ng/mL), and ECOG PS (0 vs. 1). The trial showed that regorafenib improved OS with an HR of 0.63 (95% CI, 0.50-0.79; P < 0.0001); median survival was 10.6 months in the regorafenib arm versus 7.8 months in the placebo arm. 13 The common AEs observed in the regorafenib-treated patients were hypertension (15%), HFSR (13%), fatigue (9%), and diarrhea (3%), and did not differ from those in previous reports regarding the treatment of colorectal cancer and GIST. 41, 42 Drug-related AEs led to interruptions or dose reductions in 202 (54%) patients and to discontinuations in 39 (10%) patients in the regorafenib group. 13 A new treatment strategy, sorafenib-regorafenib sequential therapy, could be a good option for patients with advanced HCC. The patients enrolled in the RESORCE study, however, were those tolerant to sorafenib. Therefore, the effectiveness and safety for patients who did not tolerate sorafenib is not guaranteed. In addition, the median duration of sorafenib treatment for patients enrolled in the RESORCE trial was 7.8 months in both the regorafenib and placebo groups. 13 These results indicate that regorafenib might be effective for patients who responded to and tolerated sorafenib for a certain amount of time. In fact, tyrosine kinases targeted by regorafenib are similar to those targeted by sorafenib, and regorafenib showed higher VEGFR-inhibiting activity than sorafenib (Table 1) , although the adopted assay systems were different between them. Further studies are needed to determine the optimal dose of regorafenib for individual cases considering the influence of previous sorafenib treatment, and to identify biomarkers for predicting clinical efficacy and survival in patients treated with regorafenib.
Lenvatinib as novel first-line therapy for HCC
Lenvatinib is an orally active TKI targeting VEGFR1-3, FGFR1-4, PDGFR-α, c-Kit, and RET (Table 2) . [43] [44] [45] Through blockage of the VEGF pathway, lenvatinib exerts antitumor activity by inhibiting angiogenesis. Lenvatinib led to significant improvements in progression-free survival (PFS) and the response rate among patients with thyroid cancer, and was approved for the treatment of locally recurrent or metastatic, progressive, radioactive iodinerefractory differentiated thyroid cancer in 2015. 46, 47 The common AEs observed in lenvatinib-treated patients with thyroid cancer included hypertension (68%), diarrhea (59%), fatigue (59%), HFSR (32%), and proteinuria (31%). 46 A phase II study to evaluate lenvatinib for HCC treatment revealed good outcomes with OS of 18.7 months, TTP of 7.4 months, an objective response rate (ORR) of 37%, and disease control rate of 78% according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). 48, 49 The most frequent AEs were hypertension (76%), HFSR (65%), decreased appetite (61%), and proteinuria (61%). Most patients required either dose reduction (74%) or drug discontinuation (22%) due to AEs. The dosage of lenvatinib was set to 12 mg once daily in 28-day cycles until disease progression or unacceptable toxicity, according to the results of a phase I dose-escalation study. 50 However, high incidence of AEs and early dose reduction were observed in the phase II study. Based on these results and pharmacokinetic analyses, the phase III study of lenvatinib in HCC proceeded with a planned dose of 8 mg in patients with lower body weight (<60 kg) and 12 mg in those with higher body weight (≥60 kg). 51 Kudo et al. recently reported the results of the phase III clinical trial to evaluate lenvatinib for HCC (REFLECT trial).
14 This study was a multicenter, randomized, openlabel, global phase III trial comparing the efficacy and safety of lenvatinib versus sorafenib as first-line treatment for patients with unresectable HCC, BCLC stage B or C, Child-Pugh class A, ECOG PS ≤ 1, and no prior systemic therapy. Patients with major portal vein tumor thrombosis (PVTT), bile duct invasion, and involvement of ≥50% of the liver were excluded. In the study, 954 patients were randomized in a 1:1 ratio to receive lenvatinib 12 mg or 8 mg once a day based on baseline body weight (n = 478), or sorafenib 400 mg twice daily (n = 476). At baseline, most patients (64%) had ECOG PS of 0, and two-thirds of the patients had macroscopic vascular invasion or extrahepatic spread, or both. Approximately half of the enrolled patients were infected with hepatitis B virus. Treatment was continued until disease progression 14 The median duration of study treatment for patients in the lenvatinib arm was 5.7 months, compared with 3.7 months in the sorafenib arm. The discrepancy between OS difference and PFS/TTP difference might result from the study design of the REFLECT trial. For example, serum AFP levels were not considered as a stratification factor, which lead to the AFP imbalance favoring the sorafenib arm. In addition, by excluding patients with Vp4 PVTT and tumor involvement of ≥50% of the liver, enrolled patients were a relatively good prognostic population in both arms, leading to long postprogression survival by post-trial treatments and a small difference in OS.
Dose reductions due to AEs were required for 37% of the lenvatinib arm and 38% of the sorafenib arm. Drug discontinuations due to AEs were needed for 9% and 7% in the lenvatinib and sorafenib arms, respectively. Grade ≥3 AEs occurred in 57% of the lenvatinib arm and 49% of the sorafenib arm. Major AEs observed in the lenvatinib arm were hypertension (42%), diarrhea (39%), decreased appetite (34%), decreased weight (31%), fatigue (30%), and proteinuria (25%), similar to those reported previously. 46 In the next section, we discuss the characteristics of AEs that can arise during treatment with lenvatinib, and potential strategies for their appropriate management.
Management of AEs during treatment with lenvatinib
Lenvatinib is a valuable treatment option for unresectable HCC. Lenvatinib is associated with the risk of AEs different from those of sorafenib, however, which could affect the treatment outcome. Therefore, careful monitoring and appropriate management of the AEs are required to ensure the continuation and efficacious use of lenvatinib. In this section, we discuss the management of hypertension, diarrhea, fatigue, and proteinuria, which are characteristic AEs of lenvatinib.
Hypertension is the most frequent AE observed in the REFLECT trial, as well as the previous report in the treatment of thyroid cancer. 46 In the REFLECT trial, hypertension of any grade was observed in 68% of the lenvatinib arm and hypertension of grade 3/4 was observed in 23%.
14 Vascular endothelial growth factor inhibitors can cause hypertension because VEGF influences vascular resistance through the production of nitric oxide and enhanced angiogenesis. 52 The median onset of hypertension was 2.3 weeks after treatment initiation in all patients, and 8 days in Japanese patients. 46 Due to the early onset and high incidence of hypertension, the assessment of preexisting cardiovascular disease before treatment and frequent monitoring of blood pressure during the beginning of lenvatinib treatment are highly recommended. 52 There are no evidence-based guidelines to define the optimum antihypertensive therapy for patients treated with VEGF pathway inhibitors. Administration of an antihypertensive agent, however, including angiotensin II receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEi), should be considered in patients with ≥140/90 mmHg in accordance with the guidelines for the management of hypertension. [53] [54] [55] Both ARB and ACEi are recommended in patients with proteinuria, which is another AE of lenvatinib, because of their renoprotective effects. 52, 55 When using calcium channels blockers (CCBs), nondihydropyridine CCBs such as diltiazem or verapamil should be avoided, as they inhibit cytochrome P450 3A4, which metabolizes VEGF inhibitors, leading to high levels of plasma VEGF inhibitors. 52, 56 Diarrhea is a common AE in TKI-treated patients. The incidence of any grade of diarrhea was 39% in the REFLECT trial.
14 The diarrhea was generally mild, however, and diarrhea of grade 3/4 was observed in only 4% of patients. Those patients require supportive therapy to prevent dehydration with an antidiarrheal drug such as loperamide. Treatment interruption should be considered in the case of grade 3/4 diarrhea and a subsequent dose reduction of lenvatinib might be necessary to resume treatment with lenvatinib.
Proteinuria develops relatively early and its median onset time after the initiation of lenvatinib is 6.1 weeks. 57 Anti-angiogenic treatments blocking VEGF are associated with the occurrence of proteinuria. [58] [59] [60] Additionally, FGFR inhibition can adversely affect podocyte function in TKI-treated patients. 61 Regular urinalysis should be planned to detect the onset of proteinuria during treatment with lenvatinib. If proteinuria is grade 3/4 (defined as urinary protein ≥3.5 g/day or a urine protein : creatinine ratio ≥3.5) or if grade 1/2 proteinuria occurs in patients with such risks as elevated serum creatinine, leg edema, or ascites, cessation of lenvatinib should be considered in consultation with a urologist. Takahashi et al. have reported cases of irreversible renal failure in sunitinib-treated patients, suggesting that VEGFR inhibitors should be withdrawn before deterioration of proteinuria. 62 Therefore, routine monitoring and appropriate management of proteinuria are essential during treatment with lenvatinib.
Fatigue is caused by various factors, and one of the major reasons is hypothyroidism. A number of reports have indicated that TKIs could induce thyroid dysfunction. 63 Tyrosine kinase inhibitor-induced hypothyroidism was reported in sorafenib-treated patients with RCC, sunitinibtreated patients with GIST, nilotinib-treated patients with chronic myeloid leukemia, and axitinib-treated patients with RCC. [64] [65] [66] [67] Therefore, an assessment of thyroid function should be considered for lenvatinib-treated patients complaining of prolonged fatigue.
In summary, during treatment with lenvatinib, in addition to blood tests, routine checks of blood pressure and urine are highly recommended. It should be emphasized that adequate management of AEs could contribute to maintaining the quality of life of patients receiving lenvatinib treatment.
Differences and effective use of lenvatinib and sorafenib
Lenvatinib is the first TKI whose non-inferiority to sorafenib is statistically confirmed as a first-line therapy for advanced-stage HCC. Therefore, both a thorough understanding of the pharmacologic features of each agent and the selection of an optimal therapy suited for each patient are needed.
Both lenvatinib and sorafenib are recommended only for patients with Child-Pugh class A liver function. Therefore, identifying the strategy for selecting the appropriate treatment such as lenvatinib, sorafenib, TACE, and HAIC, for advanced HCC patients with good liver function, is important. There are also several differences between lenvatinib and sorafenib (Table 2) . First, lenvatinib strongly inhibits VEGF receptors compared with sorafenib (IC 50 of VEGFR2, 3-4 vs. 26 for lenvatinib and sorafenib; IC 50 of VEGFR3, 5.2 vs. 15-30 for lenvatinib and sorafenib, respectively), which could lead to the high ORR of lenvatinib. [43] [44] [45] Second, lenvatinib targets molecules such as FGFR1-4, c-Kit, and RET, which are not targeted by sorafenib. Third, the AE profile differs significantly between lenvatinib and sorafenib. Although the risk of HSFR and diarrhea is relatively higher in patients treated with sorafenib, the risk of hypertension and proteinuria is higher in those using lenvatinib. Finally, lenvatinib has no evidence-based second-line therapy, whereas patients whose disease progress while on sorafenib can shift to regorafenib (although regorafenib is not recommended for patients who did not respond to or tolerate sorafenib). Further studies are necessary to examine the possibility of using sorafenib or regorafenib as a second-line therapy after lenvatinib failure.
The identification of predictive factors for treatment response enables us to use TKIs more effectively. Ten years have passed since the approval of sorafenib for HCC, and there have been several reports on the predictors of treatment response and survival in patients treated with sorafenib. Personeni et al. reported the prognostic usefulness of a decrease in the serum AFP in HCC patients treated with sorafenib. 68 The AFP response (>20% decrease in AFP during 8 weeks of treatment with sorafenib) is a prognostic factor of survival (HR = 0.42; P < 0.002). Kuzuya et al. showed that the absence of disappearance of arterial tumor enhancement, AFP ratio of >1.2, and remnant liver function (two or more increments of Child-Pugh score) after 2 weeks of treatment with sorafenib were significant and independent predictors of worse survival. 69 Ogasawara et al. revealed that the emergence of new extrahepatic lesions during sorafenib treatment was an independent indicator of a poor prognosis. 70 Howell et al. reported in a global multicenter, prospective study that the development of sorafenib-induced toxicity including diarrhea, hypertension, and HFSR was associated with prolonged OS. 71 In addition, analyses of HCC samples in patients treated with sorafenib revealed that fibroblast growth factor (FGF)3/FGF4 amplification and FGF19 amplification were frequently observed in responders to sorafenib. 72, 73 With regard to lenvatinib, further work is needed from both basic and clinical viewpoints to identify predictive factors for treatment response and survival.
Ongoing challenges for HCC treatment
Hepatocellular carcinoma occurs in the background of chronic hepatitis or liver cirrhosis. As mentioned earlier, diverse genomic changes and abnormal activation of signaling pathways are involved in hepatocarcinogenesis. 20, 22, 23, 74, 75 In addition, different tumors in the same liver, even different regions in the same tumor, show various molecular profiles, which could determine the growth properties of the tumors and patients' clinical outcome. [76] [77] [78] [79] Therefore, different therapeutic strategies from those used for cancers in other organs, as well as multiple approaches in combination with conventional treatments, such as surgical resection, ablation, TACE, HAIC, and previously approved TKIs, are needed (Fig. 2) .
In October 2017, cabozantinib, an oral multikinase inhibitor targeting MET, RET, AXL, and VEGFR1-3, was announced to improve median OS compared with placebo in patients with advanced HCC who have previously received sorafenib in the global phase III CELESTIAL trial (NCT01908426). 80 Cabozantinib was approved in 2012 for the treatment of progressive metastatic medullary thyroid cancer following a successful phase III trial. 81 In the CELESTIAL trial, cabozantinib significantly improved OS (10.2 vs. 8.0 months for cabozantinib and placebo, respectively; HR = 0.76 [95% CI, 0.63-0.92]; P = 0.0049) and PFS (5.2 vs. 1.9 months; HR = 0.44 [95% CI, 0.36-0.52]; P < 0.001), and the ORR was 4% versus 0.4% (P = 0.0086). The most common grade 3/4 AEs with a higher incidence in the cabozantinib versus placebo arm included HFSR (17% vs. 0%), hypertension (16% vs. 2%), increased aspartate aminotransferase (12% vs. 7%), fatigue (10% vs. 4%), and diarrhea (10% vs. 2%). In September 2017, the US Food and Drug Administration granted an accelerated approval to nivolumab, a fully human immunoglobulin G4 programmed cell death-1 (PD-1) immune checkpoint inhibitor (ICI) monoclonal antibody, for patients with HCC previously treated with sorafenib. The phase I/II CheckMate-040 trial enrolled 262 patients with advanced HCC. 82 The accelerated approval was based on a subset of 154 patients in the trial whose disease worsened during treatment with sorafenib. Among the 154 patients, 3 had a complete response to nivolumab and 19 had a partial response. In addition, tumors stopped growing (stable disease) for at least 6 months in 40% of the patients. Furthermore, remarkable prolongation of the median survival (sorafenib-naïve patients, 28.6 months vs. sorafenib-experienced patients, 15.6 months) was reported from an updated analysis of the CheckMate-040 trial. 80 A randomized phase III trial of nivolumab versus sorafenib as first-line treatment with advanced-stage HCC is ongoing (NCT02576509). 80 In addition, a phase III trial of pembrolizumab, another anti-PD-1 antibody as compared to placebo is also ongoing (KEYNOTE-240, NCT02702401). 80 Several clinical trials testing various combination regimens including anti-PD-1/programmed death ligand-1 (PD-L1) antibody plus anti-CTLA-4 antibodies (ipilimumab or tremelimumab) and anti-PD-1/PD-L1 antibody plus TKIs are currently underway. For example, a phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib for patients with unresectable HCC is ongoing (NCT03298451). The single-arm trial of ipilimumab plus nivolumab therapy for advanced-stage HCC patients is also ongoing (NCT01658878). As trials of combined TKI plus ICI, a regimen of lenvatinib plus pembrolizumab for advanced-stage HCC is expected (NCT03006926). In addition to the steady implementation of clinical trials, identification of the predictors of the treatment response and survival in HCC patients treated with novel TKIs or ICIs is crucial.
CONCLUSIONS
After a decade of sorafenib as the only available molecular targeting agent for HCC, regorafenib as second-line therapy and lenvatinib as another first-line therapeutic agent have finally been approved. In the near future, ICI-based combination regimens with another ICI or TKI will be expected as a breakthrough for patients with unresectable HCC. Hepatologists should become highly familiar with the pharmacologic characteristics of each drug as well as the appropriate management of possible AEs. Further exploration of biomarkers that predict the treatment response and survival in patients with HCC are also expected.
